|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Thrombolytic Agent for Stroke Therapy |
|
| Management |
| Dr. Itschak Lamensdorf, CEO |
| |
|
|
| |
|
| Keywords |
| Cardiology, Neurology, Regenerative Medicine. Ischemia, Stroke, Acute Myocardial Infarction, Pulmonary Embolism, Peripheral Arterial and Venous Occlusion, Thrombosis. |
|
|
|
|
|
|
| Description |
|
Thrombotech is developing innovative peptides that can address tPA unmet needs extending its therapeutic time window and reducing its adverse side effects....
view more
|
|
| Products / Services |
The first lead compound of Thrombotech is a peptide that when combined together with virtually every thrombolytic agent existing today (e.g., Urokinase, Alteplase) Retavase, TNKase) can increase its PAI-1 resistance and abolish its vasoactivity. The co-administration of the peptide can significantly reduce the bleeding side effects and increase the therapeutic time window of current thrombolytic treatment, thus improving significantly both its efficacy and safety profile.
|
|
| Technology / Differentiation |
| Thrombotech has developed a distinctive lead compound to be used as safer thrombolytic agents: a Plasminogen Activator Inhibitor-1 (PAI-1) derived peptide. Thrombotech's animal studies (3 different species in several independent sites) exhibited high efficacy and safety of its lead compounds. |
|
| Market / Customers |
Approximately 750,000 patients suffer new ischemic strokes annually in the USA, about 150,000 of who die as a consequence. Worldwide, the incidence of stroke is estimated to be 2-2.5 per thousand, resulting in 4.5 million deaths per year. The direct and indirect annual costs of stroke in the United States currently are estimated to exceed $51 billion. Notwithstanding more than 50 years of effort to develop effective treatments, tPA remains the only FDA-approved treatment for acute stroke. tPA improves clinical outcome, but only if administered within 3 hours of the onset of an ischemic stroke. In addition to its brief therapeutic window, the increased side-effects including symptomatic intra-cerebral hemorrhage (ICH) have constrained its clinical use to only 3% of patients who might otherwise benefit from intervention. Additional indications of Thrombotech's products include: Acute Myocardial Infraction (AMI) ~ (900,000 patients/year), Pulmonary Embolism (PE) (~ 650,000 patients/year), and Peripheral Arterial and Venous Occlusion (~ 1,000,000 patients/year).
|
|
| Status |
| Thrombotech has licensed and owns various patents / patent applications for the complex technology and the thrombolytic use of its lead peptide. GMP production of the peptide, further toxicity tests, and completion of requirements for an IND request are expected within 2009. The company is seeking additional investment in order to initiate clinical trials. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members